Skip to main navigation
Close
Menu
Main navigation
Advocacy
Issue Overview
#Rx4StateSavings
#4GRxANTED
#MarkupMadness
State Advocacy
GDUFA/BsUFA User Fees
Biosimilars Council
Action Center
Our Impact
Join
About Us
Generic Quality
About AAM
Our Team
Our Members
Generic Medicines
Biosimilars Council
Meet Our Board
Social Commitment
Careers
Contact Us
Stories
Events
Resources
All Resources
Drug Shortages White Paper
2023 Savings Report
Biosimilars Patient Resource Center
Biosimilar Research & Studies
Press Releases
Blog
Founders Blogs
Amicus Briefs
Take Action
Breadcrumb
Association for Accessible Medicines
Resources
Resources
Share
Find up-to-date information on generics and biosimilars
Filter Resources
Issues
Biosimilar User Fee Act (BsUFA)
Biosimilars
Complex Generics
Drug Approval Process (GDUFA)
Drug Prices
Drug Shortages
Generic Drug Labeling
Generic Supply Chain
IP Issues
Low Income Subsidies (LIS in Part D)
Medicaid
Medicare
NAFTA
Patent Reform
Patient Stories
Pharmaceutical Waste Take Back
Preventing Drug Abuse
Quality
REMS/Sample Acquisition Remedies
State Initiatives
Tariffs
Trade
Transparency
User Fees
Resource Type
Blog
Amicus Brief
Press Release
Infographic
Video
Report
Fact Sheet
Presentation
Press Release
Nov 14, 2018
| Rachel Schwartz
Poll Results: Americans’ Attitudes on U.S. Trade Policy and Drug Pricing
Infographic
Nov 14, 2018
| Erica Klinger
Poll Results: USMCA Trade Agreement
Press Release
Nov 5, 2018
| Rachel Schwartz
Patient Groups, Retirees, American Workers, Doctors, Manufacturers, Join to Voice Concern Over Proposed Trade Deal
Fact Sheet
Nov 1, 2018
| Jewel Smith
AAM Associate Member Fact Sheet
Fact Sheet
Nov 1, 2018
| Jewel Smith
AAM Regular Member Fact Sheet
Blog
Oct 30, 2018
| Chip Davis
Prescription Drug Safety: Education and Impact
Blog
Oct 29, 2018
| Kristin Murphy
Women in Health Policy Gather at AAM
Amicus Brief
Oct 17, 2018
| Jeff Francer
HELSINN v. TEVA
Press Release
Oct 17, 2018
| Rachel Schwartz
AAM Files Amicus Brief in Helsinn v Teva
Press Release
Oct 11, 2018
| Rachel Schwartz
AAM Statement on FDA Record Generic Approvals
Blog
Oct 10, 2018
| Chip Davis
Generic and Biosimilars Approvals Are Only Half the Story
Blog
Oct 9, 2018
| Jeff Francer
Op-Ed: The New NAFTA Could Thwart President's Promise to Lower Prescription Drug Costs
Load More
Advocacy
Issue Overview
#Rx4StateSavings
#4GRxANTED
#MarkupMadness
State Advocacy
GDUFA/BsUFA User Fees
Biosimilars Council
Action Center
Our Impact
Join
About Us
Generic Quality
About AAM
Our Team
Our Members
Generic Medicines
Biosimilars Council
Meet Our Board
Social Commitment
Careers
Contact Us
Stories
Events
Access! 2024
GRx+Biosims 2023
Resources
All Resources
Drug Shortages White Paper
2023 Savings Report
Biosimilars Patient Resource Center
Biosimilar Research & Studies
Press Releases
Blog
Founders Blogs
Amicus Briefs
Take Action